NM_000051.4:c.670A>G
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 0P and 3B. BP4_ModerateBP6
The NM_000051.4(ATM):āc.670A>Gā(p.Lys224Glu) variant causes a missense change. The variant allele was found at a frequency of 0.000101 in 1,613,070 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000051.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATM | NM_000051.4 | c.670A>G | p.Lys224Glu | missense_variant | Exon 7 of 63 | ENST00000675843.1 | NP_000042.3 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000854 AC: 13AN: 152164Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000836 AC: 21AN: 251098Hom.: 0 AF XY: 0.0000663 AC XY: 9AN XY: 135706
GnomAD4 exome AF: 0.000103 AC: 150AN: 1460906Hom.: 0 Cov.: 32 AF XY: 0.0000991 AC XY: 72AN XY: 726800
GnomAD4 genome AF: 0.0000854 AC: 13AN: 152164Hom.: 0 Cov.: 31 AF XY: 0.0000807 AC XY: 6AN XY: 74328
ClinVar
Submissions by phenotype
not provided Uncertain:9Benign:1
- -
ATM: BP4 -
Available data are insufficient to determine the clinical significance of the variant at this time. The available data on the frequency of this variant in large general population databases was not informative towards the evaluation of its pathogenicity (http://gnomad.broadinstitute.org). This variant has been identified in at least one individual with clinical features of ataxia-telangiectasia. Computational tools disagree on the variant's effect on normal protein function. -
The ATM c.670A>G (p.Lys224Glu) variant has been reported in the published literature in an individual affected with ataxia-telangiectasia along with another pathogenic ATM variant (PMID: 10817650 (2000)) and in individuals with breast cancer (PMID: 19781682 (2009), 20305132 (2010), 26689913 (2015), 27616075 (2016), 28779002 (2017)), melanoma (PMID: 34262154 (2021)), and prostate cancer (PMID: 33436325 (2021)). This variant has also been observed in reportedly healthy individuals (PMID: 19781682 (2009), 33471991 (2021), see also LOVD (http://databases.lovd.nl/shared)). The frequency of this variant in the general population, 0.0002 (10/50682 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded conflicting predictions that this variant is benign or damaging. Based on the available information, we are unable to determine the clinical significance of this variant. -
Observed in the compound heterozygous state with an ATM truncating variant in a patient with ataxia-telangiectasia (PMID: 10817650); In silico analysis indicates that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 26689913, 24825865, 19781682, 23585524, 22114986, 28779002, 29659569, 29522266, 29449575, 26580448, 27616075, 29684080, 25186627, 20305132, 31422574, 31920950, 31567591, 33436325, 32095738, 33471991, 30303537, 34326862, 34262154, 36029002, 33850299, 35534704, 10817650, 38136308) -
- -
- -
- -
- -
- -
Ataxia-telangiectasia syndrome Uncertain:3Benign:1
This variant is interpreted as a Uncertain Significance - Insufficient Evidence, for Ataxia telangiectasia, in Autosomal Recessive manner. The following ACMG Tag(s) were applied: PM2 => Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. -
- -
- -
This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. -
not specified Uncertain:3
- -
- -
Variant summary: ATM c.670A>G (p.Lys224Glu) results in a conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8.9e-05 in 258294 control chromosomes (gnomAD and publications). This frequency is not higher than expected for a pathogenic variant in ATM causing Ataxia-Telangiectasia (8.9e-05 vs 0.004), allowing no conclusion about variant significance. c.670A>G has been reported in the literature in an individual affected with Ataxia-Telangiectasia (Li_2000) and in several individuals affected with various types of cancers (example, Tavtigian_2009, Kraus_2016, Paulo_2018, Dalmasso_2021, Karlsson_2021). The variant has also been observed in unaffected control individuals (example, Tavtigian_2009, Girard_2019). These data do not allow any conclusion about variant significance. At-least one publication reports experimental evidence evaluating an impact on protein function, however, does not allow convincing conclusions about the variant effect (Navrkalova_2013). 12 ClinVar submitters (evaluation after 2014) cite the variant as uncertain significance and three ClinVar submitter (evaluation after 2014) cites it as likely benign. Based on the evidence outlined above, the variant was classified as uncertain significance. -
Hereditary cancer-predisposing syndrome Uncertain:2Benign:1
The p.K224E variant (also known as c.670A>G), located in coding exon 6 of the ATM gene, results from an A to G substitution at nucleotide position 670. The lysine at codon 224 is replaced by glutamic acid, an amino acid with similar properties. This variant was reported in an individual with ataxia telangiectasia who also carried an ATM pathogenic mutation, however, detailed clinical information and the phase of the two detected alterations were not provided (Li A and Swift M. Am. J. Med. Genet. 2000 May;92:170-7). This alteration has been detected in 1/4112 breast cancer patients and 1/2399 healthy control individuals across numerous studies (Tavtigian S et al. Am. J. Hum. Genet. 2009 Oct;85:427-46). This alteration has also been identified in breast, pancreatic, prostate and melanoma cohorts, as well as in a pediatric leukemia case (Zhang J et al. N. Engl. J. Med. 2015 Dec;373(24):2336-2346; Decker B et al. J. Med. Genet. 2017 11;54(11):732-741; Kraus C et al. Int. J. Cancer. 2017 Jan;140:95-102; Bradbury et al. JCO Precis. Oncol. 2018 Apr;2; Hauke J et al. Cancer Med, 2018 04;7:1349-1358; Li C et al. Melanoma Res. 2020 Jun;30(3):247-251; Karlsson Q et al. Eur Urol Oncol, 2021 08;4:570-579). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. -
- -
- -
Familial cancer of breast Uncertain:2
This variant has been reported in the literature in individuals with breast cancer (Tavtigian 2009, Bernstein 2010, Lu 2015, Kraus 2017) and in an individual with ataxia-telangiectasia who had a frameshift variant in the ATM gene on the other allele (Li 2000). This variant has an overall allele frequency of 0.00009 in the Broad Institute gnomAD Browser (https://gnomad.broadinstitute.org/). In silico analyses indicate this is an evolutionarily conserved residue. Thus, it is unknown at this time whether this variant increases cancer risk. PP3; PM3 -
- -
ATM-related disorder Uncertain:1
The ATM c.670A>G variant is predicted to result in the amino acid substitution p.Lys224Glu. This variant was reported in the compound heterozygous state with another variant in a patient with ataxia telangiectasia (Li et al. 2000. PubMed ID: 10817650). It was also reported in a patient with triple negative breast cancer and a family history of cervical and pancreatic cancer (Kraus et al. 2016. PubMed ID: 27616075, Suppl. Table 4). This variant has also been reported in additional individuals with breast cancer (Bernstein et al. 2010. PubMed ID: 20305132, Suppl. Table 2; Lu et al. 2015. PubMed ID: 26689913, Suppl. Table 12). However, in another study, it was reported at similar frequencies in cases and controls (Tavtigian et al. 2009. PubMed ID: 19781682, Suppl. Table 2). This variant is reported in 0.016% of alleles in individuals of European (Non-Finnish) descent in gnomAD and has conflicting interpretations regarding its pathogenicity in ClinVar, ranging from likely benign to uncertain (https://www.ncbi.nlm.nih.gov/clinvar/variation/142522/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at